L3VLUP
ProSign in

DNA · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DNAAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DNA
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterDNAAMGN
Q3 2020none listed holders, n.a.16 holders, $16.3bn
Q4 2020none listed holders, n.a.19 holders, $14.0bn
Q1 2021none listed holders, n.a.16 holders, $14.5bn
Q2 2021none listed holders, n.a.23 holders, $13.8bn
Q3 2021none listed holders, n.a.24 holders, $11.6bn
Q4 2021none listed holders, n.a.21 holders, $10.4bn
Q1 2022none listed holders, n.a.23 holders, $9.9bn
Q2 2022none listed holders, n.a.28 holders, $9.7bn
Q3 2022none listed holders, n.a.21 holders, $7.9bn
Q4 2022none listed holders, n.a.24 holders, $9.3bn
Q1 2023none listed holders, n.a.22 holders, $8.4bn
Q2 2023none listed holders, n.a.26 holders, $7.4bn
Q3 2023none listed holders, n.a.26 holders, $8.7bn
Q4 2023none listed holders, n.a.24 holders, $8.4bn
Q1 2024none listed holders, n.a.25 holders, $6.7bn
Q2 2024none listed holders, n.a.20 holders, $8.0bn
Q3 20245 holders, $62m21 holders, $8.8bn
Q4 20244 holders, $72m20 holders, $8.2bn
Q1 20254 holders, $43m25 holders, $12.0bn
Q2 20254 holders, $80m20 holders, $10.2bn
Q3 20255 holders, $104m17 holders, $10.4bn
Q4 20254 holders, $52m19 holders, $18.0bn
Q1 20262 holders, $37m15 holders, $21.4bn
Q2 20263 holders, $61m23 holders, $24.9bn
DNA

Ginkgo Bioworks Holdings Inc

Holders
4
Reported value
$52m
Buyers
16
Sellers
7

Breadth +9 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
19
Reported value
$18.0bn
Buyers
13
Sellers
22

Breadth -9 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only DNA (4)

Baillie Gifford & Co, Caxton Associates LLP, Glenview Capital Management LLC, Viking Global Investors LP

Only AMGN (19)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →